These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26389682)

  • 61. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
    Sink KM; Holden KF; Yaffe K
    JAMA; 2005 Feb; 293(5):596-608. PubMed ID: 15687315
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.
    Heilman KM; Nadeau SE
    Neurotherapeutics; 2022 Jan; 19(1):99-116. PubMed ID: 35013934
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches.
    Corbett A; Ballard C
    Evid Based Med; 2016 Feb; 21(1):25. PubMed ID: 26701197
    [No Abstract]   [Full Text] [Related]  

  • 64. Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia.
    Ahmed M; Malik M; Teselink J; Lanctôt KL; Herrmann N
    Drugs Aging; 2019 Jul; 36(7):589-605. PubMed ID: 30957198
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease.
    Zhong K; Cummings J
    Expert Rev Neurother; 2024 Sep; ():1-9. PubMed ID: 39344050
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.
    Wang LY; Shofer JB; Rohde K; Hart KL; Hoff DJ; McFall YH; Raskind MA; Peskind ER
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):744-51. PubMed ID: 19700947
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Treatment of neuropsychiatric symptoms in Alzheimer's disease].
    Kaufer D
    Rev Neurol; 2002 Nov 1-15; 35(9):846-50. PubMed ID: 12436383
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
    Peters ME; Vaidya V; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Avramopoulos D;
    J Geriatr Psychiatry Neurol; 2016 Mar; 29(2):59-64. PubMed ID: 26303700
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.
    Kindermann SS; Dolder CR; Bailey A; Katz IR; Jeste DV
    Drugs Aging; 2002; 19(4):257-76. PubMed ID: 12038878
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
    Tao Y; Peters ME; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Munro CA
    Am J Alzheimers Dis Other Demen; 2018 Nov; 33(7):450-457. PubMed ID: 29969907
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Atypical neuroleptics as a treatment of agitation and anxiety in Alzheimer's disease: risks or benefits.
    Moretti R; Torre P; Antonello RM; Pizzolato G
    Expert Rev Neurother; 2006 May; 6(5):705-10. PubMed ID: 16734518
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
    Omerovic M; Hampel H; Teipel SJ; Buerger K
    World J Biol Psychiatry; 2008; 9(1):69-75. PubMed ID: 17886162
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Preliminary pilot study of cyproterone acetate for the treatment of aggressive behavior associated with severe dementia].
    Caparros-Lefebvre D; Dewailly D
    Rev Neurol (Paris); 2005 Nov; 161(11):1071-8. PubMed ID: 16288172
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.
    Ruthirakuhan MT; Herrmann N; Gallagher D; Andreazza AC; Kiss A; Verhoeff NPLG; Black SE; Lanctôt KL
    Contemp Clin Trials Commun; 2019 Sep; 15():100385. PubMed ID: 31338476
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antipsychotics in Alzheimer's Disease: Current Status and Therapeutic Alternatives.
    Maziero MP; Rocha NP; Teixeira AL
    Curr Alzheimer Res; 2023; 20(10):682-691. PubMed ID: 38409713
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia.
    Tampi RR; Joshi P; Marpuri P; Tampi DJ
    World J Psychiatry; 2020 Apr; 10(4):29-33. PubMed ID: 32399396
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms.
    Woodward MR; Harper DG; Stolyar A; Forester BP; Ellison JM
    Am J Geriatr Psychiatry; 2014 Apr; 22(4):415-9. PubMed ID: 23597932
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction.
    Senanarong V; Cummings JL; Fairbanks L; Mega M; Masterman DM; O'Connor SM; Strickland TL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):14-20. PubMed ID: 14560060
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimal nonpharmacological management of agitation in Alzheimer's disease: challenges and solutions.
    Millán-Calenti JC; Lorenzo-López L; Alonso-Búa B; de Labra C; González-Abraldes I; Maseda A
    Clin Interv Aging; 2016; 11():175-84. PubMed ID: 26955265
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
    Barak Y; Plopski I; Tadger S; Paleacu D
    Int Psychogeriatr; 2011 Nov; 23(9):1515-9. PubMed ID: 21492498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.